



# PHYOX: A SAFETY AND TOLERABILITY STUDY OF DCR-PHXC IN PRIMARY HYPEROXALURIA TYPES 1 AND 2: PROOF-OF-CONCEPT DATA

## Summary

- Observed reduction of 24Hr Uox following a single administration of DCR-PHXC in both PH1 and PH2 participants is a promising sign of DCR-PHXC's potential potency and duration of action.
- Based on a combination of multiple-dose animal data and single-dose human data, it is anticipated that a multi-dose regimen of DCR-PHXC will show even more pronounced and sustained 24Hr Uox reductions.
- DCR-PHXC is expected to enter a pivotal Phase 2/3 trial in Q1 2019.

**Figure 1. Mean Oxalate-to-Creatinine Ratio Over Time, Following Single Administration DCR-PHXC**





Figure 1 Note: At 1.5 mg/kg, n=5 at all time points, except where \* denotes data point where only 3 participants are included. At 3.0 mg/kg, n=4 at all time points, except where \* denotes data point where only 3 participants are included. Results based on availability of data as of 01 October 2018.

# DCR-HBVS: RNAi-BASED TREATMENT FOR HEPATITIS B VIRUS

## Summary

- Observed reduction in HBsAg to below the lower limit of detection after a single injection of DCR-HBVS at 3 mg/kg
- Silences multiple viral genes, thus acting like a combination therapy
- DCR-HBVS is expected to enter clinical development in Q1 2019

**Figure 2. Reduction in HBsAg Following Single Administration of DCR-HBVS, (standard mouse HBV transfection model)**



## CONTACT

### General:

**James B. Weissman**  
Chief Business Officer  
(617) 612-6214  
jweissman@dicerna.com

### Media:

**Alex Van Rees**  
SmithSolve Communications  
(973) 442-1555 x111  
alex.vanrees@smithsolve.com

### Investors:

**Paula Schwartz**  
Rx Communications Group  
(917) 322-2216  
pschwartz@rxir.com